Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1995 1
1996 1
1997 1
1998 5
2008 1
2012 1
2013 2
2015 3
2016 6
2018 3
2019 3
2020 4
2021 6
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Results by year

Filters applied: . Clear all
Page 1
Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease.
Lipson DA, Crim C, Criner GJ, Day NC, Dransfield MT, Halpin DMG, Han MK, Jones CE, Kilbride S, Lange P, Lomas DA, Lettis S, Manchester P, Martin N, Midwinter D, Morris A, Pascoe SJ, Singh D, Wise RA, Martinez FJ. Lipson DA, et al. Among authors: lettis s. Am J Respir Crit Care Med. 2020 Jun 15;201(12):1508-1516. doi: 10.1164/rccm.201911-2207OC. Am J Respir Crit Care Med. 2020. PMID: 32162970 Free PMC article. Clinical Trial.
Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial.
Pascoe S, Barnes N, Brusselle G, Compton C, Criner GJ, Dransfield MT, Halpin DMG, Han MK, Hartley B, Lange P, Lettis S, Lipson DA, Lomas DA, Martinez FJ, Papi A, Roche N, van der Valk RJP, Wise R, Singh D. Pascoe S, et al. Among authors: lettis s. Lancet Respir Med. 2019 Sep;7(9):745-756. doi: 10.1016/S2213-2600(19)30190-0. Epub 2019 Jul 4. Lancet Respir Med. 2019. PMID: 31281061 Clinical Trial.
Blood eosinophil levels as a biomarker in COPD.
Brusselle G, Pavord ID, Landis S, Pascoe S, Lettis S, Morjaria N, Barnes N, Hilton E. Brusselle G, et al. Among authors: lettis s. Respir Med. 2018 May;138:21-31. doi: 10.1016/j.rmed.2018.03.016. Epub 2018 Mar 15. Respir Med. 2018. PMID: 29724389 Free article. Review.
Reporting Adverse Drug Reactions in Product Labels.
Crowe B, Chuang-Stein C, Lettis S, Brueckner A. Crowe B, et al. Among authors: lettis s. Ther Innov Regul Sci. 2016 Jul;50(4):455-463. doi: 10.1177/2168479016628574. Ther Innov Regul Sci. 2016. PMID: 30227021
Misinterpretation of time-to-first event curves can lead to inappropriate treatment.
Hartley B, Criner GJ, Dransfield MT, Halpin DMG, Han MK, Jones CE, Kilbride S, Lange P, Lipson DA, Lomas DA, Martin N, Martinez FJ, Singh D, Wise RA, Lettis S. Hartley B, et al. Among authors: lettis s. Eur Respir J. 2019 Sep 5;54(3):1900634. doi: 10.1183/13993003.00634-2019. Print 2019 Sep. Eur Respir J. 2019. PMID: 31488584 Free article. No abstract available.
Prognostic value of clinically important deterioration in COPD: IMPACT trial analysis.
Han MK, Criner GJ, Dransfield MT, Halpin DMG, Jones CE, Kilbride S, Lange P, Lettis S, Lipson DA, Lomas DA, Martin N, Martinez FJ, Wise RA, Naya IP, Singh D. Han MK, et al. Among authors: lettis s. ERJ Open Res. 2021 Mar 8;7(1):00663-2020. doi: 10.1183/23120541.00663-2020. eCollection 2021 Jan. ERJ Open Res. 2021. PMID: 33718490 Free PMC article.
A single blood eosinophil count measurement is as good as two for prediction of ICS treatment response in the IMPACT trial.
Bafadhel M, Barnes N, Bourke SC, Compton C, Criner GJ, Dransfield MT, Halpin DMG, Han MK, Hartley B, Jones CE, Lange P, Lettis S, Lipson DA, Lomas DA, Martin N, Martinez FJ, Wise R, Singh D. Bafadhel M, et al. Among authors: lettis s. Eur Respir J. 2021 Sep 23;58(3):2004522. doi: 10.1183/13993003.04522-2020. Print 2021 Sep. Eur Respir J. 2021. PMID: 34385263 Free article. No abstract available.
38 results